Cingulate (CING) Non Operating Income (2021 - 2026)
Cingulate's (CING) quarterly Non Operating Income came in at -$552655.0 in Q4 2025, down 822.33% YoY from $76510.0 in Q4 2024, and up 3.56% on a QoQ basis from -$573058.0 in Q3 2025.
Cingulate (CING) Non Operating Income (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Non Operating Income data on file, last reported at -$552655.0 in Q4 2025.
- Quarterly Non Operating Income fell 822.33% year-over-year to -$552655.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.1 million (down 1254.68% YoY) and the FY2025 annual result came in at -$1.4 million, down 1471.61% from the prior year.
- Non Operating Income advanced to -$552655.0 in Q4 2025, from -$573058.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $76510.0 in Q4 2024 to a low of -$573058.0 in Q3 2025.
- A 5-year average of -$110745.7 and a median of -$24260.0 in 2024 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income surged 255.17% — and 2023, when it plunged 3133.93%.
- Tracing CING's Non Operating Income over 5 years: stood at -$6599.0 in 2021, then slumped by 1870.03% to -$130002.0 in 2022, then fell by 5.8% to -$137546.0 in 2023, then surged by 155.63% to $76510.0 in 2024, then slumped by 822.33% to -$552655.0 in 2025.
- The last three Non Operating Income figures came in at -$552655.0 (Q4 2025), -$573058.0 (Q3 2025), and -$96656.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -53.64 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -51.63 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Cingulate | 70.68 Mn | 70.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -141,276.00 |
| Dec 31, 2025 | -552,655.00 |
| Sep 30, 2025 | -573,058.00 |
| Mar 31, 2025 | -96,656.00 |
| Dec 31, 2024 | 76,510.00 |
| Sep 30, 2024 | 50,483.00 |
| Jun 30, 2024 | -3,497.00 |
| Mar 31, 2024 | -24,260.00 |
| Dec 31, 2023 | -137,546.00 |
| Sep 30, 2023 | -229,380.00 |
| Jun 30, 2023 | -253,940.00 |
| Mar 31, 2023 | -154,892.00 |
| Dec 31, 2022 | -130,002.00 |
| Sep 30, 2022 | -58,885.00 |
| Jun 30, 2022 | 8,370.00 |
| Mar 31, 2022 | 5,833.00 |
| Dec 31, 2021 | -6,599.00 |
| Sep 30, 2021 | -10,559.00 |
| Jun 30, 2021 | -9,676.00 |
| Mar 31, 2021 | -3,759.00 |